{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-003722","form_type":"8-K","ticker":"PAYS","cik":"0001496443","company_name":"Paysign, Inc.","filed_at":"2026-05-12T20:05:48+00:00","discovered_at":"2026-05-12T20:07:00.310971+00:00","generated_at":"2026-05-12T21:31:58.569748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Paysign Q1 2026 revenue $28.04M (+50.8% YoY); pharma up 81.9%, net income $5.44M","bullets":["Revenue $28.04M, up 50.8% YoY; pharma $15.68M (+81.9%), plasma $11.75M (+24.9%).","Net income $5.44M ($0.09 diluted EPS) vs $2.59M ($0.05); adj. EBITDA $10.59M, up 113.4%.","Operating margin 23.8% vs 13.4% YoY; gross margin 65.0% from 62.9% on pharma mix shift.","Active patient affordability programs 135 (net +45 in 12 months); plasma centers 573 (net +89).","Q2 2026 guidance: revenue $26.2M-$26.7M; full-year revenue $106.5M-$110.5M, net income $13M-$16M."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003722","json":"https://secwatch.observer/filing/0001683168-26-003722.json","markdown":"https://secwatch.observer/filing/0001683168-26-003722.md","text":"https://secwatch.observer/filing/0001683168-26-003722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/0001683168-26-003722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/paysign_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:31:58.569748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c68ee0c0bce2abe247e25a9c2e83cdcd53507390","claim":"Paysign, Inc. reported first quarter 2026 results: revenue $28.04 million, net income $5.44 million, or $0.09 per diluted share, EPS $0.09 per diluted share.","evidence_excerpt":"for the life sciences industries, today announced financial results for the first quarter 2026. First Quarter 2026 Financial Highlights · First quarter 2026 revenues of $28.04 million, up 50.8% from f irst quarter 2025 · First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus f irst quarter 2025; added 45 net patient","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/0001683168-26-003722-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$28.04 million"},{"label":"Net income","value":"$5.44 million, or $0.09 per diluted share"},{"label":"EPS","value":"$0.09 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}